Haoxi Health Technology Ltd, a company specializing in advertising services with a market capitalization of $4.53 million, has announced the scheduling of its annual general meeting (AGM) of shareholders. The notice, filed with the Securities and Exchange Commission (SEC) on Thursday, December 19, 2024, calls upon shareholders to participate in the upcoming AGM. According to InvestingPro analysis, the company is currently trading below its Fair Value, presenting a potential opportunity for investors interested in undervalued stocks.
The notice and proxy card for the AGM were attached as Exhibits 99.1 and 99.2, respectively, in the company's filing. These documents are intended to provide shareholders with the necessary information to exercise their voting rights at the meeting. While the SEC does not review and comment on these notices for foreign private issuers like Haoxi Health, the company urges its shareholders to review the notice carefully for important information regarding the AGM.
Haoxi Health Technology, incorporated under the organization name 07 Trade & Services, is based in the Chaoyang District of Beijing, China. The company has a fiscal year-end on June 30 and is registered under the SIC code for advertising agencies.
Shareholders can access the notice and other relevant documents filed or submitted by the company on the SEC's website or the company's own site. Additionally, shareholders may request copies of the filings at no charge either through the company's website or by writing to the company's principal executive office in Beijing.
The company also disclosed that its directors and executive officers might be considered participants in the solicitation of proxies from shareholders in connection with the AGM. Details about these individuals and their interests in the company, whether direct or indirect, are described in the notice filed with the SEC.
Haoxi Health Technology's CEO, Zhen Fan, signed off on the SEC filing, underscoring the company's commitment to keeping its shareholders informed and involved in crucial company decisions.
This news is based on the most recent SEC filing by Haoxi Health Technology Ltd and serves to inform shareholders and the public of the company's forthcoming AGM. Despite the stock's significant YTD decline of 97.63%, the company maintains a GOOD Financial Health Score of 2.65 according to InvestingPro metrics, suggesting potential resilience in its fundamental operations.
In other recent news, Beijing-based Haoxi Health Technology Limited has set the price for its follow-on public offering. The company aims to raise $12 million in gross proceeds by offering 4 million units at $3.00 each. Each unit includes a share of Class A Ordinary Share or a pre-funded warrant to purchase such a share, and two series of warrants to purchase additional Class A Ordinary Shares.
EF Hutton LLC, the sole bookrunner for the offering, has been granted an option to purchase up to an additional 600,000 units to cover over-allotments. This offering is expected to close around September 20, 2024, and the proceeds are intended for working capital, corporate purposes, technology acquisitions or investments, and hiring experienced staff.
The offering is being conducted on a firm commitment basis, with the details available in a prospectus following an effective registration statement filed with the U.S. Securities and Exchange Commission. These are the most recent developments for Haoxi Health Technology Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.